Telomeric 3′ overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma

International Journal of Cancer

Volumn 123, Issue 2, 2008, Pages 264-272

  Lee, Jae Eun ^a   Oh, Bong Kyeong ^a   Choi, Jinsub ^a   Young, Nyun Park ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cytokeratin 19; Hepatitis B virus; Hepatocellular carcinoma; hTERT; Telomere; Telomeric 3 overhang

Indexed keywords

CYTOKERATIN 19; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERE BINDING PROTEIN; TELOMERIC REPEAT BINDING FACTOR 1; POT1 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL DIVISION; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MITOSIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; STEM CELL; TELOMERE; UPREGULATION; VIRUS EXAMINATION; ENZYMOLOGY; GENETICS; LIVER TUMOR; MIDDLE AGED; VIROLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B, CHRONIC; HUMANS; KERATIN-19; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER; TELOMERASE; TELOMERE; TELOMERE-BINDING PROTEINS; TELOMERIC REPEAT BINDING PROTEIN 1;

EID: 44949194700     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23376     Document Type: Article

References (44)

1. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997;88:657-66.
2. McElligott R, Wellinger RJ. The terminal DNA structure of mammalian chromosomes. EMBO J 1997;16:3705-14.
3. Wright WE, Tesmer VM, Liao ML, Shay JW. Normal human telomeres are not late replicating. Exp Cell Res 1999;251:492-9.
4. Blackburn EH. Switching and signaling at the telomere. Cell 2001;106:661-73.
5. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. Mammalian telomeres end in a large duplex loop. Cell 1999;97:503-14.
6. Baumann P, Cech TR. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 2001;292:1171-5.
7. Kim SH, Kaminker P, Campisi J. Telomeres, aging and cancer: in search of a happy ending. Oncogene 2000;21:503-11.
8. Keys B, Serra V, Saretzki G, von Zglinicki T. Telomere shortening in human fibroblasts is not dependent on the size of the telomeric-3′- overhang. Aging Cell 2004;3:103-9.
9. Stewart SA, Ben-Porath I, Carey VJ, O'Connor BF, Hahn WC, Weinberg RA. Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet 2003;33:492-6.
10. Ishikawa F. Telomere crisis, the driving force in cancer cell evolution. Biochem Biophys Res Commun 1997;230:1-6.
11. Murnane JP, Sabatier L. Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. Bioessays 2004;26:1164-74.
12. Gisselsson D, Hoglund M. Connecting mitotic instability and chromosome aberrations in cancer-can telomeres bridge the gap? Semin Cancer Biol 2005;15:13-23.
13. Gisselsson D, Jonson T, Yu C. Centrosomal abnormalities, multipolar mitosis, and chromosomal instability in head and neck tumors with dysfunctional telomeres. Br J Cancer 2002;87:202-7.
14. Zhai Y, Zhou G, Deng G, Xie W, Dong X, Zhang X, Yu L, Yang H, Yuan X, Zhang H, Zhi L, Yao Z, Shen Y, Qiang B, He F. Estrogen receptor α polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 2006;130:2001-9.
15. Oh BK, Chae KJ, Park C, Kim K, Lee W, Han KH, Park YN. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis. J Hepatol 2003;39:786-92.
16. Oh BK, Kim YJ, Park C, Park YN. Up-regulation of telomere-binding proteins, TRF1, TRF2 and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol 2005;166:73-80.
17. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73.
18. Plentz RR, Caselitz M, Bleck JS, Gebel M, Flemming P, Kubicka S, Manns MP, Rudolph KL. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatocellular carcinoma. Hepatology 2004;40:80-6.
19. Kim SH, Kaminker P, Campisi J. TIN2, a new regulator of telomere length in human cells. Nat Genet 1999;23:405-12.
20. Stansel RM, de Lange T, Griffith JD. T-loop assembly in vitro involves binding of TRF2 near the 3′telomeric overhang. EMBO J 2001;20:5532-40.
21. Anno K, Hayashi A, Takahashi T, Mitsui Y, Ide T, Tahara H. Telomerase activation induces elongation of the telomeric single-strand overhang, but does not prevent chromosome aberrations in human vascular endothelial cells. Biochem Biophys Res Commun 2007;353:926-32.
22. Wu L, Multani AS, He H, Cosme-Blanco W, Deng Y, Deng JM, Bachilo O, Pathak S, Tahara H, Bailey SM, Deng Y, Behringer RR, et al. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 2006;126:49-62.
23. Churikov D, Wei C, Price CM. Vertebrate POT1 restricts G-overhang length and prevents activation of a telomeric DNA damage check-point but is dispensable for overhang protection. Mol Cell Biol 2006;26:6971-32.
24. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
25. Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, Park YN. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004;40:298-304.
26. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006;25:3818-22.
27. Wu PC, Lai VC, Fang JW, Gerber MA, Lai CL, Lau JY. Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 1999;31:965-6.
28. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006:49:138-51.
29. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-56.
30. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006;351:820-4.
31. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851-7.
32. Yamamoto T, Uenishi T, Ogawa M, Ichikawa T, Hai S, Sakabe K, Tanaka S, Kato H, Mikami S, Ikebe T, Tanaka H, Ito S, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-16.
33. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-50.
34. Yoon DS, Jeong J, Park YN, Kim KS, Kwon SW, Chi HS, Park C, Kim BR. Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. Yonsei Med J 1999;40:472-7.
35. Edmonson HA, Steiner PE. Primary carcinoma of the liver: a study of 100cases among 48900 necropsies. Cancer 1954;7:462-503.
36. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
37. Kruk PA, Rampino NJ, Bohr VA. DNA damage and repair in telomeres: relation to aging. Proc Natl Acad Sci USA 1995;3:258-62.
38. Koo JS, Seong JK, Park C, Yu DY, Oh BK, Oh SH, Park YN. Large liver cell dysplasia in hepatitis B virus x transgenic mouse liver and human chronic hepatitis B virus-infected liver. Intervirology 2005;48:16-22.
39. Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H, Yasui W. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 2004;64:523-9.
40. Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003;63:5021-7.
41. Garcia-Aranda C, de Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P. Correlations of telomere length, telomerase activity, and telomeric-repeat bindina factor 1 expression in colorectal carcinoma. Cancer 2006;106:541-51.
42. Gertler R, Rosenberg R, Strieker D, Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B, Nekarda H, Siewert JR. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004:22:1807-14.
43. Patel MM, Parekh LJ, Jha FP, Sainger RN, Patel JB, Patel DD, Shah PM, Patel PS. Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck 2002;24:1060-7.
44. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007;96:1020-4.